Paul Rowe became a Partner in the Litigation Department at Wachtell, Lipton, Rosen and Katz in 1985. He focuses on representing corporations and directors in litigation involving M&A transactions, proxy contests, shareholder class actions involving allegations of breach of fiduciary duty, derivative actions and special committees.
Mr. Rowe has written extensively on subjects relating to fiduciary duties and other corporation and securities law issues. In recent years, Mr. Rowe has been prominent in various high-profile M&A litigations, representing NYSE Euronext in litigation arising out of its proposed business combination with Deutsche Borse; Novartis in litigations arising out of its acquisition of Alcon; representing CONSOL Energy in litigation arising out of its acquisition of CNX Gas Corporation; representing Goldman Sachs in litigation arising out of the buy-out of Kinder Morgan Inc.; and representing Wells Fargo in litigation arising out of its purchase of Wachovia Corp.
Mr. Rowe has engaged in various professional activities in the M&A field, including serving as a member of the Board of Advisors of Harvard Law School's Corporate Governance Forum (since 2006); teaching (as an Adjunct Professor of Law at University of Pennsylvania Law School); and writing (notably, Pills, Polls and Professors: A Reply to Professor Gilson (2002) co-authored with Martin Lipton); in addition to numerous panel appearances at PLI and other professional education conferences.